SAN FRANCISCO, Oct. 8, 2015 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will present an overview of the
Company's pain and oncology portfolio during an Investor and
Analyst R&D Day being hosted today from 12:30 - 3:30 p.m. Eastern Time in New York City.
Leading experts in immuno-oncology will provide an overview of
the current landscape in immuno-oncology and the need for new
T-cell stimulatory agents, such as NKTR-214 and NKTR-255. For
the first time, Nektar will announce new data for single-agent
NKTR-214, including data in a preclinical model of Lewis Lung carcinoma. Details of the
NKTR-214 Phase 1/2 clinical program and biomarker strategy will be
presented. NKTR-214 is a CD122-biased immune-stimulatory
cytokine designed to preferentially stimulate the production of
CD8-positive T-cells. The Company will present new
preclinical data for its next immuno-oncology candidate, NKTR-255,
a new immune-stimulatory cytokine designed to improve T-cell memory
by targeting the IL-15 pathway. The company will also discuss its
new IDO inhibitor program, NKTR-218, which could increase IDO
inhibition activity within the tumor micro-environment.
Pain management specialists will discuss opioid-induced
constipation and new first-in-class medicine MOVANTIK™, as well as
review the regulatory landscape for abuse-deterrent
analgesics. New in vitro manipulation and extraction data
will be presented for NKTR-181, a first-in-class, mu-opioid
analgesic investigational drug candidate with a novel molecular
structure designed to reduce abuse liability.
The experts will also participate in two separate panel
discussions on current treatment practices and share their
perspectives on the medical need for new treatment options.
"Today's presentations will highlight the significant promise of
our internally discovered programs, particularly in
immuno-oncology, which have the potential to drive the next stage
of growth for Nektar," stated Howard W.
Robin, President and Chief Executive Officer of Nektar. "We
are leveraging our technology to create compelling new
immuno-oncology drug candidates that access new cytokine biology to
expand T-cell populations and improve T-cell memory in order to
train the immune system to fight cancer. In the area of pain,
NKTR-181 is a new opioid molecule that represents a completely new
class of pain medicine which could allow us to maintain the
efficacy of traditional opioids, while potentially reducing the
serious risks of misuse, abuse and diversion."
Webcast Information
The live webcast from will start at 12:30
p.m. ET and can be accessed by visiting the investor
relations section of Nektar's website at http://www.nektar.com. To
ensure a timely connection to the webcast, it is recommended that
users register 15 minutes prior to the scheduled webcast. This
webcast will be archived on Nektar's website for 30 days following
the event.
About Nektar
Nektar Therapeutics has a robust R&D pipeline in pain,
oncology, hemophilia and other therapeutic areas. In the area of
pain, Nektar has an exclusive worldwide license agreement with
AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved
once-daily oral peripherally-acting mu-opioid receptor antagonist
(PAMORA) medication for the treatment of opioid-induced
constipation (OIC), in adult patients with chronic, non-cancer
pain. The product is also approved in the European Union as
MOVENTIG® (naloxegol) and is indicated for adult patients with
OIC who have had an inadequate response to laxatives. The
AstraZeneca agreement also includes NKTR-119, an earlier stage
development program that is a co-formulation of MOVANTIK and an
opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for
chronic pain conditions, is in Phase 3 development. NKTR-171, a
wholly-owned new sodium channel blocker being developed as an oral
therapy for the treatment of peripheral neuropathic pain, is in
Phase 1 clinical development. In hemophilia, BAX 855, a
longer-acting PEGylated Factor VIII therapeutic is in Phase 3
development conducted by partner Baxter. A BLA for BAX 855 was filed by
Baxter to the US FDA in December,
2014 and is currently under review. In anti-infectives, Amikacin
Inhale is in Phase 3 studies conducted by Bayer Healthcare as an
adjunctive treatment for intubated and mechanically ventilated
patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
AstraZeneca's MOVANTIK™, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE is a trademark of Baxalta Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will" and similar references to future periods.
Examples of forward-looking statements include, among others,
statements we make regarding the value and potential of our
polymer conjugate technology and research and development pipeline.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated
events and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others, (i) scientific discovery of new medical
breakthroughs is an inherently uncertain process and the future
success of the application of our technology platform to potential
new drug candidates is therefore highly uncertain and unpredictable
and one or more research and development programs could fail; (ii)
patents may not issue from our patent applications for our drugs
and drug candidates, patents that have issued may not be
enforceable, or additional intellectual property licenses from
third parties may be required; and (iii) the outcome of any
existing or future intellectual property or other litigation
related to our drugs and drug candidates and those of our
collaboration partners. Other important risks and
uncertainties set forth in our Annual Report on Form 10-Q filed
with the Securities and Exchange
Commission on August 6, 2015. Any forward-looking
statement made by us in this press release is based only on
information currently available to us and speaks only as of the
date on which it is made. We undertake no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Media
Nadia Hasan of WCG
212-257-6738
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-reports-on-advancements-with-pain-and-oncology-clinical-pipeline-at-investor-and-analyst-rd-day-300156696.html
SOURCE Nektar Therapeutics